This CPB has been revised to state that Food and Drug Administration (FDA)-approved endobronchial valve (e.g., the Zephyr Valve System) is considered medically necessary for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation.